Back to Search
JUAN CORTES, D.O.
D.O.
Family Medicine Physician
NPI: 1508957804IndividualAccepts Medicare
Specialties, Licenses & Credentials
Family Medicine PhysicianPrimary
Family Medicine
Code: 207Q00000X
212652(NY)
Education
NEW YORK COLLEGE OF OSTEO MEDICINE OF NEW YORK INSTITUTE OF TECHNOLOGY
Class of 1997
Research & Publications (20)
Inhibition of IGF-IR tyrosine kinase induces apoptosis and cell cycle arrest in imatinib-resistant chronic myeloid leukaemia cells.
PMID 19508387·J Cell Mol Med·2010
7-preclinical
BCR-ABL truncation due to premature translation termination as a mechanism of resistance to kinase inhibitors.
PMID 19332983·Acta Haematol·2009
6-review
Nonpegylated liposomal doxorubicin (TLC-D99), paclitaxel, and trastuzumab in HER-2-overexpressing breast cancer: a multicenter phase I/II study.
PMID 19118059·Clin Cancer Res·2009
3-trial
Phase II study of rabbit anti-thymocyte globulin, cyclosporine and granulocyte colony-stimulating factor in patients with aplastic anemia and myelodysplastic syndrome.
PMID 19242494·Leukemia·2009
3-trial
First-line therapy for chronic myeloid leukemia: Past, present, and future.
PMID 19306355·Am J Hematol·2009
6-review
Prognostic significance of CD20 expression in adults with de novo precursor B-lineage acute lymphoblastic leukemia.
PMID 18703706·Blood·2009
8-other
Imatinib has limited therapeutic activity for hypereosinophilic syndrome patients with unknown or negative PDGFRalpha mutation status.
PMID 19013640·Leuk Res·2009
8-other
Effective treatment of acute promyelocytic leukemia with all-trans-retinoic acid, arsenic trioxide, and gemtuzumab ozogamicin.
PMID 19075265·J Clin Oncol·2009
8-other
Efficacy of imatinib dose escalation in patients with chronic myeloid leukemia in chronic phase.
PMID 19117345·Cancer·2009
8-other
Phase II study of imatinib mesylate as therapy for patients with systemic mastocytosis.
PMID 19193436·Leuk Res·2009
3-trial
Dasatinib treatment for Philadelphia chromosome-positive leukemias: practical considerations.
PMID 19195046·Cancer·2009
6-review
Bleeding diathesis in patients with chronic myelogenous leukemia receiving dasatinib therapy.
PMID 19280591·Cancer·2009
3-trial
Failure to achieve a complete hematologic response at the time of a major cytogenetic response with second-generation tyrosine kinase inhibitors is associated with a poor prognosis among patients with chronic myeloid leukemia in accelerated or blast phase.
PMID 19282457·Blood·2009
3-trial
A pharmacodynamic study of the FLT3 inhibitor KW-2449 yields insight into the basis for clinical response.
PMID 19029442·Blood·2009
3-trial
Reproductive medicine meets human embryonic stem cell (hESC) research: the need to adjust the regulatory framework to actual expectations and potential detrimental consequences of hESC research.
PMID 18692797·Fertil Steril·2009
8-other
Circulating heat shock protein 70 and progression in patients with chronic myeloid leukemia.
PMID 18715642·Leuk Res·2009
8-other
Data courtesy of the U.S. National Library of Medicine (NLM). Ltrl is not affiliated with or endorsed by NLM.
Contact & Hours
- Address
- 124 BAY RIDGE AVE
BROOKLYN, NY 11220 - Phone
- (718) 836-2199
Quick Facts
- NPI
- 1508957804
- Entity Type
- Individual
- Gender
- Male
- Medicare
- Accepted
- Specialties
- 1
- Locations
- 1
- Years in Practice
- 29
- Publications
- 20
Are you this provider?
Claim Your Profile